Efficacy of fludrocortisone for symptom relief in patients with autonomic syncope and hypotensive phenotype.
文献摘要
Aim To assess the efficacy of fludrocortisone therapy in patients with autonomic syncope and hypotensive phenotype. Methods and results Multicentre, prospective, non-randomized study. Fludrocortisone therapy was guided by clinician experience and supported by two 24-hour ambulatory blood pressure monitoring (ABPM) assessments-one before treatment start (ABPM 1) and one after drug optimization (ABPM 2). Primary endpoint: reduction of the syncope burden and presyncopal symptoms based on validated semi structured questionnaires. Secondary endpoint: hypotensive episodes on ABPM. In a cohort of 94 patients treated with fludrocortisone (median age 38 [IQR 21-57]) years, 83% females), 16 patients stopped therapy due to side effects, occurring during optimization (#11) or follow-up (#5). A total of 83 patients were analysed. The average 24-hour systolic blood pressure (SBP) increased from 106.3 ± 8.2 mmHg at ABPM 1 to 112.3 ± 9.3 at ABPM 2 (p = 0.0001). The number of daytime SBP drops Conclusion Fludrocortisone therapy was associated with reduced hypotension and the burden of symptoms both in younger and in older patients. Side effects lead to discontinuation of therapy in 17% of cases.